Centessa Pharmaceuticals PLC Form 4 insider transactions

Director Arjun Goyal acquired 48,000 share options in Centessa Pharmaceuticals on June 25, 2024.

Director Mary Lynne Hedley acquired 48,000 share options in Centessa Pharmaceuticals on June 25, 2024, according to a Form 4 filing.

Director Mathias Hukkelhoven acquired 48,000 share options in Centessa Pharmaceuticals on June 25, 2024.

Director Samarth Kulkarni acquired 48,000 share options in Centessa Pharmaceuticals, vesting on the earlier of the first anniversary of the grant date or the next annual shareholder meeting.

Director Carol Stuckley acquired 48,000 share options in Centessa Pharmaceuticals on June 25, 2024, according to a recent SEC filing.

Director Brett I.W. Zbar of Centessa Pharmaceuticals plc reports the acquisition of share options, though disclaims beneficial ownership except for pecuniary interest.

David M. Chao, Chief Administrative Officer of Centessa Pharmaceuticals plc, disposed of 10,385 ordinary shares to cover tax withholding obligations related to vesting restricted share units.

Gregory Weinhoff, CFO of Centessa Pharmaceuticals, reports the disposal of shares to cover tax withholding obligations related to vesting restricted share units.

CEO Saurabh Saha disposed of 36,263 ordinary shares of Centessa Pharmaceuticals to cover tax withholding obligations related to vesting restricted share units.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the disposal of 7,520 ordinary shares to cover tax withholding obligations related to vesting restricted share units on March 31, 2024.

Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, disposed of 6,419 ordinary shares to cover tax withholding obligations related to vesting restricted share units.

Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, reported the exercise of share options and subsequent sale of ordinary shares on March 25, 2024, according to a Form 4 filing with the SEC.